We aimed to control the gene expression of vascular endothelial growth factor (VEGF) and angiopoietin-1 (Ang-1) in the ischemic heart to explore the feasibility of sequential, timely and controlled multigene expression as a means of improving therapeutic angiogenesis in vivo. Adult rabbit myocardial infarction models were surgically established (n ¼ 120). Hypoxia-inducible factor-1a-hypoxic response element (HIF1a-HRE) and Tet (tetracycline)-On advanced gene control systems were reconstructed for controlled expression of the human VEGF 165 (hVEGF 165 ) and Ang-1 genes, respectively. Recombinant adeno-associated viruses (rAAV)-9HRE-hVEGF 165 and rAAV-TRE-Tight-Ang-1 were delivered into the ischemic myocardium for 12 weeks. Reverse transcription-polymerase chain reaction, western blotting and immunofluorescence staining were used to detect gene and protein expression. Vessel functionality, vascular permeability and animal cardiac function were also evaluated. Under the control of the HIF1a-HRE and Tet-On gene control systems, the expression of the exogenous hVEGF 165 and Ang-1 genes was consistent in the ischemia control. In the sequential group, we found that the number of functional vessels with a larger diameter and more vascular branches was increased, and vascular permeability was significantly reduced. In addition, animal heart function was significantly improved compared with the non-sequential and hVEGF 165 -or Ang-1-only groups (Po0.05, Po0.05, respectively). Sequential, timely and controlled expression of the hVEGF 165 and Ang-1 genes in vivo is a new therapeutic angiogenesis strategy that can effectively promote functional vessel regeneration and can improve cardiac function in ischemic heart disease.
INTRODUCTION
Therapeutic angiogenesis induced by angiogenic genes is a promising treatment for chronic myocardial ischemia. 1, 2 It is generally recognized that vascular endothelial growth factor (VEGF) is a highly specific vascular growth factor that effectively promotes new vessel sprouting in the initial phase of angiogenesis. 3 However, VEGF-induced new vessels lack a vascular basement membrane and a-smooth muscle actin (a-SMA)-positive pericytes. Increased vascular permeability inevitably increases vascular exudation. Angiopoietin-1 (Ang-1), a Tie family member, and its ligand act to connect endothelial cells closely with the surrounding blood vessels through VE-cadherin and integrins. [4] [5] [6] In the late phase of angiogenesis, Ang-1 has an important role in promoting vascular maturation and contributes to enhanced integrity of the endothelial cell barrier. 7 Therefore, for therapeutic angiogenesis, the introduction of both early-and late-phase angiogenic factors to modify the immature vasculature and enhance new vessel function has attracted considerable interest.
Lee et al. 8 analyzed the expression levels of VEGF and Ang-1 in patients with acute myocardial infarction (AMI) and found that VEGF was upregulated early after the initial injury (o6 weeks); Ang-1 expression was subsequently increased, suggesting that the timing of VEGF expression is quite different from that of Ang-1 expression in the endogenous repair of human myocardial infarction.
On the basis of the pathologic characteristics of human endogenous infarcted myocardial repair, we hypothesized that if the expression of exogenous VEGF and Ang-1 is synchronized with endogenous neovascularization in the target organ, the outcome of therapeutic angiogenesis will be improved in the ischemic heart. To ensure that the expression of the transferred VEGF and Ang-1 genes is synchronized with endogenous angiogenesis in the ischemic heart, timely and sequentially controlled in vivo expression of these genes is essential. Currently, the ideal multigene expression control system in the ischemic heart is still under investigation.
We previously verified the feasibility of sequentially controlled expression of VEGF and Ang-1 in vitro. 9 In this study, we simultaneously delivered the human VEGF 165 (hVEGF 165 ) and Ang-1 genes to the animal ischemic myocardium and regulated gene expression in a sequential manner with both a recombinant, hypoxia-inducible factor-1a-hypoxic response element (HIF-1a-HRE) and an advanced Tet (tetracycline)-On double-controlled gene expression system. We aimed to explore the feasibility of this new approach to sequential time-controlled multigene expression for future applications in multiple-gene therapy in ischemic heart disease.
RESULTS

Transferred gene expression in vivo
Reverse transcription-polymerase chain reaction (RT-PCR) showed that hVEGF 165 mRNA expression was upregulated 2 weeks after AMI, peaked at 4 weeks post-AMI and later was gradually downregulated in the sequential group. By 12 weeks after AMI, hVEGF 165 mRNA expression reverted back to its pre-ischemic levels. In this study, Dox (doxycycline hydrochloride) was added at the sixth week of AMI, and overexpression of Ang-1 mRNA was identified at the eighth week post-AMI (2 weeks after Dox induction). Ang-1 mRNA expression remained at this higher level until 12 weeks AMI (Figures 1a and c) .
Western blotting detected hVEGF 165 protein expression in the sequential group, which peaked at 6 weeks after AMI, but hVEGF 165 protein expression in the ischemic control was notably low during the 12-week AMI period (Po0.001). Ang-1 was induced at 6 weeks AMI with Dox treatment, and Ang-1 protein expression was detected in the sequential group after 8 weeks of AMI.
However, Ang-1 was not identified in the absence of Dox induction within 1-6 weeks post-AMI (Po0.001) (Figures 1b and d) .
Microvessel density measurement
In the sequential group, the total microvessel density (MVD) of the CD31-positive vessels was significantly higher than that in the non-sequential, Ang-1 and ischemic control groups (Po0.01), but was lower than that in the hVEGF 165 -only group (Po0.05) (Figure 2 ).
In the sequential group, numerous CD31-positive vessels were observed in the margin of the infarcted myocardium next to which the virus was injected, and the regenerated vessels were well distributed with an even diameter. Although MVD in the hVEGF 165 -only group was larger than the sequential and normal control groups, hyperplasia of endothelial cells and disarranged new vessels featuring an immature vessel structure were also observed (Supplementary Figure S2) .
Increased new functional vessels By the end of 12 weeks AMI, the number of CD31 and a-SMA double-positive vessels with a large vascular diameter in the sequential group was higher than that in the other groups Figure 1 . Expression of the hVEGF 165 and Ang-1 genes in vivo. (a and c, RT-PCR determination; b and d, western blot determination). hVEGF 165 and Ang-1 mRNA and protein expression were consistent with that of the ischemic control group. (a) Under the control of the HRE-HIF system, the expression of hVEGF 165 mRNA in the sequential group was upregulated after AMI, peaked at 4 weeks and reversed back to pre-ischemia levels by the end of 12 weeks AMI (n ¼ 3). (b) hVEGF 165 protein in the sequential group was upregulated after AMI, peaked at 6 weeks and reversed back to pre-ischemia levels by the end of 12 weeks AMI. m Po0.01 versus pre-ischemia and 12 weeks AMI levels (n ¼ 3). (c) Ang-1 mRNA overexpression in the sequential group was detected at the 8th week post-AMI with Dox induction and remained at an increased level until the end of 12 weeks AMI (n ¼ 3). (d) Ang-1 protein expression in the sequential group, beginning at the 8th week post-AMI, was detected with Dox induction. # Po0.01 versus the levels at 0-6 weeks AMI (n ¼ 3).
Controlled expression of hVEGF 165 and Ang-1 in the ischemic heart H Zhang et al (Supplementary Figure S3A) . The maturation vessel index in the sequential group was significantly larger than that in the nonsequential, hVEGF 165 , Ang-1 and ischemic control groups (Po0.05). There was no difference between the sequential group and the sham-operated or normal control groups (P40.05) (Figure 3a) . The results of the lectin vessel perfusion showed that in the sequential group, the number of fluorescein isothiocyanate-lectinperfusing vessels with a larger vascular diameter was increased, and we noted that a portion of the perfusing vessels had extended into the infarcted myocardium (Supplementary Figure  S3B) . The perfusion vessel index (PVI) in the sequential group was larger than those of the non-sequential, hVEGF 165 , Ang-1 and ischemic control groups (Po0.05) (Figure 3b ).
Quantitative measurement of vascular permeability
The results indicated that the Evans Blue-stained areas of the infarcted myocardium from the hearts in the sequential group were smaller compared with the hVEGF 165 group, indicating that less dye residue remained in the myocardium. The normal control heart was dye-free (Supplementary Figure S4) .
The amount of dye that leaked out of the coronary artery and infiltrated the myocardium in the sequential group was significantly less than was observed from the non-sequential, hVEGF 165 and Ang-1 groups (Po0.05). We found that a large quantity of Evans Blue resided in the myocardium in the hVEGF 165 -only group (Figure 4) .
Morphology of perfusing vessels
Morphological observations showed that the lectin-perfusing vessels in the sequential group were well arranged and that certain vascular branches were connected to one another in an organized network architecture, whereas the vessels in the VEGF group had a tiny diameter and poorly ordered morphology (Supplementary Figure S5) . The average diameter of the vessels in the sequential group was significantly larger than that in the nonsequential, Ang-1, hVEGF 165 and ischemic control groups (Po0.05) and similar to that in the normal control (P40.05). Meanwhile, there was more vessel branching in the sequential group relative to that in the non-sequential and normal control groups but less branching than in the hVEGF 165 group (Po0.05) ( Figure 5 ).
Distribution of VEGFR2-positive vessels
In normal myocardium, few VEGFR2-positive endothelial cells were detected. In the VEGF group, the number of misarranged bud endothelial cells with high VEGFR2 expression was significantly increased relative to the other groups. In the sequenced and non-sequenced control groups, increased numbers of VEGFR2 sprouting vessels were found 12 weeks after AMI, and the majority of these sprouting vessels were well arranged and oriented toward the margin of the ischemic myocardium. This result suggests that new vessels were still sprouting after 12 weeks AMI. In contrast, only a few VEGFR2-positive sprouting vessels were detected in the ischemic control by the end of 12 weeks AMI (Supplementary Figure S6) .
Improved heart systolic function At 12 weeks after AMI, the animals in each group were examined by echocardiography to evaluate cardiac performance parameters. The results showed that the heart systolic function in the sequential group was significantly improved and that the left ventricular end-diastolic dimension (LVEDD) and left ventricular Figure 2 . MVD of the newly formed vessels. MVD determination showed that MVD in the sequential group was significantly larger than the other groups. *Po0.01 versus other groups, except those in the hVEGF 165 alone, sham-operated and normal control groups, which were P40.05 (n ¼ 3). ND, not determined. Figure 3 . Determinations of the maturation vessel index (MVI) and perfusing vessel index (PVI). (a) MVI determination showed that MVI in the sequential group was significantly higher than those in the non-sequential, hVEGF 165 , Ang-1 and ischemic control groups, *Po0.05. There was no difference between the sequential group and sham-operated or normal control groups, P40.05 (n ¼ 3). (b) PVI determination showed that PVI in the sequential group was significantly higher than that in the non-sequential, hVEGF 165 , Ang-1 and ischemic control groups, *Po0.05. There was no difference between the sham-operated and normal control groups, P40.05 (n ¼ 3). ND, not determined.
end-systolic dimension (LVESD) values were lower than that in the other groups (Po0.05). In addition, the FS% value in the sequential group was also higher than that in the other groups (Po0.05) ( Table 1 and Supplementary Figure S7 ).
DISCUSSION
It is well documented that angiogenesis is a complex event in which multiple factors may exert their activities at different phases. 4 Angiogenesis within tissues relies on two sequential phases: an early phase that strictly depends on the presence of an early angiogenic factor (that is, VEGF) and a late phase in which vessel maturation is induced by a late angiogenic factor (that is, Ang-1). In the early stages of blood vessel growth that are promoted by the expression of angiogenic genes, VEGF induces endothelial cell proliferation and filopodia division to form the tip cells that advance toward the high concentration of VEGF. Thus, VEGF guides the new sprouting vessel.
10,11 VEGF overexpression is sufficient to facilitate the continuous extension of the filopodia and vascular sprouting. However, the morphology of new vessels at this stage is unstable because of the loosening of the tight junctions between the endothelial cells, resulting in increased vascular permeability. During the late phase, VEGF is not only obsolete but also detrimental for vessel functionality and pericyte regeneration. 12, 13 Ang-1, one of the late angiogenic factors, plays a central role in enhancing vascular maturation by initiating a Tekdependent signaling cascade associated with endothelial cells. This signaling limits the MT1-MMP level in the tip cells and prevents vascular sprouting.
14 Several researchers believe that VEGF is capable of activating related proteases and helping endothelial cells to move out of the blood vessel wall to generate new blood vessels. However, Ang-1 cannot activate associated proteases; thus, the divided endothelial cells are left in their original intravascular lumens without producing a vascular bud. 15 Multiple gene transfer, rather than a single gene delivery, is increasingly accepted as a strategy of angiogenic treatment, especially in the ischemic heart. However, repeated viral vector transfer of a single therapeutic gene in vivo may risk an immune reaction and possible side effects during the multiple invasive gene transfer procedures. Therefore, a simultaneous delivery of the multiple genes into the diseased heart could overcome the shortcomings of repeated administration of one or more genes and achieve safe and effective expression of the multiple therapeutic genes. To achieve the therapeutic benefit from sequentially controlled multiple gene expression and reduce possible side effects during long-term overexpression of the transferred genes, accurate control of gene expression is crucial. In this study, we adopted a dual gene control system to control the expression of the transferred hVEGF 165 and Ang-1 genes sequentially. Our results show that under timely gene control, the overall pattern of transferred hVEGF 165 and Ang-1 expression was fully coincident with that of endogenous rabbit VEGF and Ang-1 expression. Administration of the combined HIF-HRE/VEGF and Tet-On/Ang-1 gene expression control system achieved a timely and controlled expression of the VEGF and Ang-1 dual therapeutic genes in vivo.
Interestingly, we detected that in both sequentially controlled and uncontrolled Ang-1 expression, the density of new vessels and the number of vessel branches was significantly lower than that in the VEGF-only group, indicating that Ang-1 blocked, at Controlled expression of hVEGF 165 and Ang-1 in the ischemic heart H Zhang et al least in part, VEGF-induced angiogenesis. Yana et al. 16 found that Ang-1 and VEGF are likely to influence different types of vascular endothelial cells; Ang-1 promotes the proliferation of the stalk and the phalanx cells, whereas VEGF facilitates the formation of tip cells. When combined, Ang-1 and VEGF simultaneously induced angiogenesis; Ang-1 not only inhibited the MT1-MMP expression of Tie 2 þ -positive stalk cells but also reduces the forward migration of VEGF-induced tip cells, resulting in an enlargement of preexisting vessels rather than an increase in the vessel number. Thus, a low level of VEGF-induced angiogenesis will ultimately predominate when angiogenesis is induced with Ang-1 and VEGF. 17 In this study, although the increase in the diameter of the new vessels was visible during the simultaneous expression of VEGF and Ang-1 genes, the numbers of the CD31/a-SMA doublepositive mature vessels and the sprouting new vessels (total number of vessel branches) were decreased, suggesting that early Ang-1 overexpression is not conducive to an increase in the level of growth of new vessels or the number of mature blood vessels. The question of when Ang-1 intervention would be most appropriate to benefit angiogenesis during combined VEGF and Ang-1 gene therapy remains to be answered.
During the neonatal period, neovascular maturation induced by Ang-1 has a critical window. 18 In the early phase of angiogenesis, the spatial distribution of VEGF and its local concentration are critical for the balance between capillary branching and sized vessel growth. 19, 20 Thus, after VEGF-induced vascular sprouting, increased Ang-1 expression may facilitate new vessel maturation during the late phase of angiogenesis. Pathophysiologically, during local self-repair of the ischemic myocardium, endogenous Ang-1 upregulation usually occurs later than the upregulation of VEGF, 10 indicating that the Ang-1 intervention after an early VEGF overexpression may be an optimally timed therapeutic approach. In our study, we found that the level of endogenous Ang-1 expression in the ischemic control group was notably low during the initial 6-week AMI and increased only slightly afterward. This result is consistent with findings from Lee et al. 8 We also note that the low level of endogenous Ang-1 expression found after the 6-week AMI was too low to contribute to the blood vessel maturation process, as verified by the assessment of new vessel maturation in the ischemic control group. On the basis of this result, we initiated the induction of exogenous Ang-1 expression at week 6 during the 12-week AMI period to coordinate the expression of exogenous and endogenous Ang-1.
Our results showed that, using the sequential gene control method, the coordination of the expression of exogenous VEGF and Ang-1 and endogenous angiogenic factors greatly improved functional angiogenesis in the rabbit ischemic heart; the morphology and function of the new vessels were better than those resulting from the instantaneous expression of these angiogenic factors. Myocardial lectin staining indicated that it was these enlarged vessels, not an increased number of microvessels, that enhanced blood perfusion by up to 1.5 times in the sequential group relative to the VEGF-alone group. We found that vascular permeability in the sequential group was significantly less than that in the non-sequential group because of the timely intervention of Ang-1. Moreover, systolic function of the animal heart in the sequential group was significantly improved compared with that in the non-sequential group. We believe that the presence of functioning new vessels and the integrity of the vascular histology contribute to a markedly increased blood perfusion in the ischemic myocardium. We also note that an undesirable hemangioma was undetected at the end of 12 weeks after AMI, indicating that it is safe to enhance angiogenesis with sequentially controlled VEGF and Ang-1 expression in vivo. Thus, compared with simultaneous multigene expression, the temporally and sequentially controlled VEGF and Ang-1 expression is an optimized therapeutic strategy for angiogenesis in the ischemic heart.
Several studies have reported that the local transplantation of human skeletal myoblasts encoding the VEGF 165 and Ang-1 genes could result in enhanced angiogenesis in animal ischemic limbs and hearts. 21, 22 In comparison, the combined approach of cell transplantation with multiple gene therapy is quite different from our method of timely and sequential VEGF 165 and Ang1 gene control. Theoretically, the angiogenic synergism of the simultaneously expressed VEGF 165 and Ang-1 genes, together with the paracrine action of HSMs, may contribute to the enhanced angiogenesis in an ischemic animal organ.
Data have indicated that cardiomyogenesis followed by in vivo VEGF-induced angiogenesis participated in reducing myocardial infarct size. 23, 24 Although cardiomyogenesis was not observed in our study, evidence from others has shown that VEGF-induced cardiomyogenesis might also contribute to the improved heart systolic function observed in our study. We have previously reported that the endogenous Nkx2-5 þ cardiac progenitor cells that reside in the bone marrow were mobilized to peripheral blood circulation in response to AMI in a predominantly organspecific manner. 25 Further investigations are needed to reveal a detailed mechanism of the effects of the endogenous bone marrow-derived cardiac progenitor cells and endothelial progenitor cells on the improvement of heart function and angiogenesis in response to the VEGF and Ang-1 gradient after AMI.
Although the sequentially controlled hVEGF 165 -and Ang1-induced new vessels showed perfect morphology and function, we found that newly formed blood vessels in the center of the infarcted myocardium were rare. We speculate that the difference between the margin and center of ischemic myocardium demonstrates that certain unknown pathological factors exist in the ischemic myocardium that prevent new vessels from entering the center of the infarcted myocardium. Therefore, to clinically attain full vascularization in ischemic myocardium, the detailed mechanisms that inhibit vessels from moving to the center of infarcted myocardium need further investigation. Controlled expression of hVEGF 165 and Ang-1 in the ischemic heart H Zhang et al
In our study, we did not measure and compare the myocardial infarct size in the ischemic heart before and after the hVEGF 165 and Ang-1 gene transfer. Morphological evidence of an altered myocardial infarct size likely explains the improved heart performance after the sequential hVEGF 165 -and Ang1-induced angiogenesis. Histologically, the smooth muscle layer is an important component in the maintenance of vessel integrity, stability and resistance to systolic compression. Moreover, arteriolar smooth muscle reacts to the physiological stimuli controlling vascular tone. In our study, further identification of a-SMA-positive cells (vascular smooth muscle cells or pericytes) was absent; evidence of arteriolar smooth muscle could strengthen the conclusion of the improved perfusion that we observed here. Therefore, the absence of a myocardial infarct size measurement and arteriolar density assessment are limitations of this study.
In conclusion, our results show that the HIF-HRE and Tet-On advanced gene expression control systems, which act as gene switches, effectively facilitate the regulated expression of multiple angiogenic growth factors. We demonstrate for the first time that a temporal, sequential gene control method, an innovative therapeutic principle that matches the physiology of the body's own endogenous vascular repair system, significantly improves ischemic heart function by increasing the number of regenerated blood vessels and resulting in a more complete vascular histology and an enhanced blood flow perfusion compared with other therapeutic approaches. This research may provide a new strategy for achieving precise gene regulation for angiogenic therapy in the treatment of ischemic heart diseases.
MATERIALS AND METHODS
Recombinant adeno-associated virus constructs and viral production
Recombinant adeno-associated virus (rAAV)-9HRE-hVEGF 165 was prepared as described previously. 26 The rAAV-9HRE-hVEGF 165 titer was 2 Â 10 12 vector genomes (vg) per ml. The Tet-On advanced system (rtTA-Rs-M2, pTRE-Tight and pTRE-Tightluc) were purchased from Clontech Inc. (Mountain View, CA, USA) and the AAV expression vectors (pSNAV) were purchased from Vector Gene Technology Company Ltd (Beijing, China). We previously constructed the pTRE-Tight-Ang-1 vector 9 (Supplementary Figure.S1 ). All vector construction was confirmed by DNA sequencing (Invitrogen, Shanghai, China). The recombinant virus titer was 1 Â 10 12 vg ml
, and the viral purity of rAAV-rtTA-Rs-M2, rAAV-TRE-Tight-Ang-1 and rAAV-TRE-Tight-luc was 498%.
Animal model and intramyocardial gene delivery
New Zealand rabbits (4-6 months old, weighing 2-2.5 kg, 2.3 ± 0.15 kg, n ¼ 120) were obtained from the Experimental Animal Center of Xuzhou Medical College. All animals received humane care in compliance with the Guideline for Care and Use of Laboratory Animals, published by (Jiangsu Province, The People's Republic of China).
The animal models of AMI were established surgically (Supplementary Method 1). For intramyocardial gene delivery, rAAV-9HRE-hVEGF 165 and rAAV-rtTA-Rs-M2/rAAV-TRE-Tight-Ang-1 at a 1:1 ratio and rAAV-rtTA-Rs-M2/ rAAV-TRE-Tight-Ang-1 (4 Â 10 10 vg) at a 1:4 ratio were delivered intramyocardially. The vectors were delivered in a final volume of 40 ml of phosphate-buffered saline (pH 7.4) with a 0.5-ml syringe and 25-G needle into four sites around the marginal zone of the ischemic myocardium. Control animals received an equivalent volume of either phosphatebuffered saline or rAAV vector expressing the LacZ and Luc reporter genes.
The animal models were randomly divided into eight groups (n ¼ 30 for Groups A and E, and n ¼ 10 for other groups, 120 total): Group A (sequential), rAAV-H9-hVEGF 165 and rAAV-rtTA-Rs-M2/rAAV-TRE-Tight-Ang-1 were transferred to the ischemic myocardium, and Dox (Sigma, St Louis, MO, USA; 10 mg kg À 1 per day) 27 was given from the 6th to the 12th week after AMI (n ¼ 30). Group B (non-sequential), rAAV-H9-hVEGF 165 and rAAVrtTA-Rs-M2/rAAV-TRE-Tight-Ang-1 were cotransferred with Dox induction immediately after AMI for 12 weeks (n ¼ 10). Group C (hVEGF 165 ), rAAV-H9-hVEGF 165 was transferred without Dox induction (n ¼ 10). Group D (Ang-1), rAAV-rtTA-Rs-M2/rAAV-TRE-Tight-Ang-1 was transferred with Dox induction immediately after AMI for a total 12 weeks (n ¼ 10). Group E (ischemic control, or blank), 40 ml phosphate-buffered saline was transferred as a solvent control (n ¼ 30). Group F (vector control), rAAV-9HRE-LacZ and rAAV-rtTA-Rs-M2/rAAV-TRE-Tight-luc were transferred into the ischemic myocardium and treated as an AAV vector control (n ¼ 10). Group G (sham-operated), the animals did not undergo any gene transfer (n ¼ 10). Group H (normal) was the normal control (n ¼ 10).
To determinate the sequentially controlled hVEGF 165 and Ang-1 gene expression, Groups A (sequential) and E (ischemic control) were re-divided into seven subgroups based on time intervals. Each time interval was 2 weeks, and the total observation period was 12 weeks. The animal hearts from Groups A and E were obtained 0 and 2, 4, 6, 8, 10 or 12 weeks after AMI for RT-PCR and western blot analysis (n ¼ 3, per time intervals). The other animals were killed by the end of the 12th week AMI for further analysis (each group ¼ 10).
Gene expression determination
RT-PCR and western blotting were conducted to detect the expressions of hVEGF 165 and Ang-1 mRNA and protein.
The primer sequences of hVEGF 165 /Ang-1, and the experimental procedures of RT-PCR and western blot analysis are shown in Supplementary Method 2.
MVD measurement
The myocardial samples from the left ventricle were immersion fixed in 4% paraformaldehyde for 24 h and were rinsed in 30% sucrose overnight (pH 7.4). The myocardium was cut into 20-mm-thick frozen sections. The slides were blocked using 10% normal goat serum and incubated with a mouse monoclonal antibody (mAb) against CD31 (Abcam, Cambridge, MA, USA; 1:20) for 1 h. The secondary antibody was a peroxidase conjugate with tetramethyl rhodamine isothiocyanate (Sigma; 1:200). The slides were examined using a fluorescence microscope (Olympus, Tokyo, Japan).
The MVD of the myocardial tissue sections in the peri-infarcted area from each group was calculated by the method we described previously 28 Briefly, using a low-power field ( Â 40), the sections were scanned, and five areas with the highest positive CD31 signal (hotspots) were selected. Microvessel counts of these areas were performed using a high-power field ( Â 200) with a computer image analyzer (HPIAS2000 color imaging analyzer system; Tongji Qianping Imaging Co., Wuhan, China). An automated microvessel count per field was computed in each hot spot. The mean microvessel count of the five selected areas was the MVD, which was expressed as the absolute number of microvessels per 0.74 mm 2 ( Â 200 magnification). All measurements were performed in a blinded manner.
New vessel maturation and stability measurement
To evaluate hVEGF 165 -and Ang-1-induced vessels, double-labeling immunofluorescence staining of CD31 and a-SMA was performed. The myocardial samples from the peri-infarcted area were cut into 20-mm-thick frozen sections and processed for immunofluorescence and subsequent imaging analysis.
The endothelium was immunostained using a mouse mAb against CD31 (Abcam; 1:20); the secondary antibody was conjugated with tetramethyl rhodamine isothiocyanate (Sigma; 1:200). After blocking with goat antimouse antibody serum, the pericytes and vascular smooth muscle cells were costained with a mouse mAb against a-SMA (Sigma; 1:250) and the secondary antibody fluorescein isothiocyanate (Sigma; 1:200). Controls were processed identically except for the omission of the primary antimouse antibody. The slides were observed using the fluorescence microscope, and the area of each CD31-and a-SMA-positive vessel was measured using the Image-Pro Plus software (Media Cybernetics Inc., Bethesda, MD, USA).
A vessel maturation index was employed to evaluate vessel maturation and stability. Vessel maturation index (%) ¼ area of a-SMA-positive vessels/ total area of CD31-positive vessels Â 100.
Analysis of vessel perfusion
To confirm the perfusion function of the vessels, fluorescent lectin staining was performed as described previously. 29 The harvested hearts were perfused with phosphate-buffered saline (pH 7.4) via the coronary artery for 5 min at a pressure of 120 mm Hg. Subsequently, 6 ml of fluorescein isothiocyanate-conjugated lectin (Sigma) at a concentration of 30 mg ml
Controlled expression of hVEGF 165 and Ang-1 in the ischemic heart H Zhang et al was perfused. Frozen lectin-perfused myocardial tissue sections (20 mm) were costained with CD31 and tetramethyl rhodamine isothiocyanateconjugated goat anti-mouse antibody (Sigma; 1:200) to evaluate the perfused vessels using the fluorescence microscope. A lectin-positive vessel was defined as a perfusing vessel. The area of each CD31-and lectinpositive vessel was measured using the Image-Pro Plus software (Media Cybernetics Inc.). A PVI was employed to evaluate the vessels with perfusion function. PVI (%) ¼ area of lectin-positive vessels/total area of CD31-positive vessels Â 100. Meanwhile, the vascular diameter and the number of lectin-perfused vessel branches were also calculated.
Vascular sprouting observation
To identify the VEGF-induced vessel tip cells, a VEGFR2 immunohistochemical stain was used. A mAb against VEGFR2 was used to visualize vessel tip cells. Frozen myocardial tissue sections (20 mm) were incubated with a mouse mAb against VEGFR2 (Abcam; 1:20) for 1 h. The secondary antibody was a peroxidase conjugate with tetramethyl rhodamine isothiocyanate (Sigma; 1:200). The slides were observed using the fluorescence microscope.
Vascular permeability measurement
To determine vascular permeability in the rabbit hearts, a Miles assay was used. 30 Two percent Evans Blue dye (30 mg kg À 1 ; Sigma) was injected intravenously 30 min before the animals were killed. After killing, the heart tissue was weighed, and the Evans Blue dye was extracted by immersion in formamide (1 ml/100 mg) overnight at 60 1C. The extract was centrifuged (7000 r.p.m. for 45 min at 4 1C). The Evans Blue dye content was determined based on absorbance at 620 nm, and the ratio between the transferred and the intact normal heart samples was calculated and normalized to the tissue weight. 31 
Animal cardiac function evaluation
The cardiac function of the animals was measured 12 weeks after AMI by echocardiography (Philips IE33, Best, The Netherlands).
The following parameters were derived from the M-mode tracing: heart rate (HR), LVEDD (mm) and LVESD (mm). LVEDD and LVESD were measured at the same time from the short-axis view just below the level of the papillary muscle within the same cardiac cycle. The left ventricular fractional shortening (LVFS) was calculated as follows: LVFS (%) ¼ (LVEDD À LVESD)/LVEDD Â 100.
All of the parameters were measured for at least three consecutive cardiac cycles and were analyzed offline by two independent observers who were blinded to the treatment status of the animals.
Statistical analyses
All of the data were expressed as the means ± s.d. and analyzed by analysis of variance and a Student-Newman-Keuls test using the SPSS13.0 software (SPSS Inc. Chicago, IL, USA). P-values of o0.05 were considered to be statistically significant.
